Zhongsheng Pharmaceutical announced that the holding subsidiary obtained top-line analysis data results for the Phase I clinical trial of RAY1225 injection, a class 1 innovative drug.

Zhitongcaijing · 03/25 10:49
Zhongsheng Pharmaceutical announced that the holding subsidiary obtained top-line analysis data results for the Phase I clinical trial of RAY1225 injection, a class 1 innovative drug.